Articles related to OSTEOARTHRITIS (OA)

A GLP-1 receptor agonist delivered directly into the knee joint received FDA Fast Track designation for osteoarthritis with synovitis, with phase 2a data not expected until 2027.

Preclinical findings point to a potential role for extracellular vesicles in cartilage repair, offering insight into future directions for osteoarthritis research.

Collagen, once relegated to cosmetic marketing, now shows potential as a legitimate adjunct in the prevention or management of age-related decline in connective tissue integrity.

If approved, retatrutide will be the first in a new class of medications combining GIP, GLP-1, and glucagon receptor agonism in a single once-weekly injection.

In a significant advancement for knee osteoarthritis treatment, LEVI-04 demonstrated pain reduction in more than 50% of treated patients, with effects lasting through 20 weeks of study.

This in-depth research opens up potential avenues for the use of ADMSCs in managing K-L grade 3 knee osteoarthritis, particularly in terms of pain and functional improvements, signifying a promising frontier in osteoarthritis treatment.